Point72 Asset Management
MNPR icon

Point72 Asset Management’s Monopar Therapeutics MNPR Stock Holding History

Point72 Asset Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-104,019
Closed -$3.72M – 2544
2025
Q2 		$3.72M Sell
104,019
-64,141
-38% -$2.33M 0.01% 1066
2025
Q1 		$6.12M Buy
168,160
+268
+0.2% +$9.66K 0.01% 853
2024
Q4 		$3.69M Buy
+167,892
New +$2.82M 0.01% 1039

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Point72 Asset Management's MNPR Position: Q3 2025 in Review

Point72 Asset Management sold out of Monopar Therapeutics (MNPR) in Q3 2025, closing a stake of 104,019 shares — an estimated $3.72M sold.

Point72 Asset Management first reported a position in MNPR in Q4 2024 and held it in 3 quarters. The position peaked at $6.12M in Q1 2025. 56 funds tracked by Wall St. Rank hold MNPR as of Q3 2025.

  • Point72 Asset Management reported no remaining Monopar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 Asset Management sold 104,019 Monopar Therapeutics shares in Q3 2025, an estimated $3.72M.
  • Point72 Asset Management first reported a position in Monopar Therapeutics in Q4 2024 and held it in 3 quarters.
  • Point72 Asset Management's Monopar Therapeutics position peaked at $6.12M in Q1 2025.
  • 56 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2025.

Based on Point72 Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.